New combo therapy aims to boost thyroid cancer treatment in kids and young adults

NCT ID NCT06458036

Recruiting now Disease control Sponsor: Children's Hospital of Philadelphia Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests whether giving the targeted drug selpercatinib for 6 months before standard radioactive iodine therapy can improve outcomes for children, adolescents, and young adults (ages 2-25) with a specific type of thyroid cancer linked to RET gene fusions. The goal is to see if selpercatinib makes cancer cells absorb more radioactive iodine, leading to better tumor shrinkage and fewer side effects. The trial will enroll 13 participants and track response rates, safety, and long-term survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selpercatinib (a targeted cancer drug) and radioactive iodine (131I) therapy
What this could lead to: If successful, this approach could make radioactive iodine therapy more effective for young patients with RET fusion thyroid cancer, potentially reducing the need for repeat treatments and lowering long-term side effects.
What could go wrong: This is a small, early-phase trial with only 13 participants, so results may not apply to everyone. Selpercatinib can cause side effects like liver problems or high blood pressure, and the combination with radioactive iodine may increase risks of lung damage or secondary cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer childhood malignant neoplasm differentiated thyroid carcinoma neoplasm thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CANCER, THYROID DIFFERENTIATED THYROID CANCER PEDIATRIC CANCER

Contacts and locations

Locations

Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Seattle Children's Hospital
TERMINATED

Seattle, Washington, 98105, United States
St. Jude Children's Research Hospital
RECRUITING

Memphis, Tennessee, 38105, United States
The Unviersity of California, San Francisco (UCSF)
NOT_YET_RECRUITING

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.